Stock VERA VERA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Delayed Nasdaq
Other stock markets
 21:00:00 18/06/2024 BST 		5-day change 1st Jan Change
35.53 USD -0.53% Intraday chart for Vera Therapeutics, Inc. -7.55% +131.01%
06-12 Vera Therapeutics, Inc. Appoints Christy Oliger to the Board CI
05-28 Vera Therapeutics Gets FDA Breakthrough Therapy Designation for Immunoglobulin A Nephropathy Treatment MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Vera Therapeutics, Inc. Appoints Christy Oliger to the Board
CI
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
GL
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
GL
Vera Therapeutics Gets FDA Breakthrough Therapy Designation for Immunoglobulin A Nephropathy Treatment
MT
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
GL
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
AQ
Vera Therapeutics Inc. Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy
CI
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
AQ
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
GL
Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
CI
Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing
MT
Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating
MT
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
GL
Vera Therapeutics : Provides Business Update and Reports First Quarter 2024 Financial Results - Form 8-K
PU
Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge
DJ
Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition
DJ
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VERA Stock
  4. News Vera Therapeutics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW